UCIBIO-NOVA FCT technology for cancer treatment licensed to BioNTech by CellmAbs CellmAbs, a spin-off biotech company from Universidade NOVA de Lisboa, announced on 9 January that it has entered into a patent assignment and license agreement with BioNTech SE (Nasdaq: BNTX, "BioNTech"), a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases.
Cecília Roque receives an ERC Proof of Concept grant Cecília Roque, leader of the Biomolecular Engineering Laboratory at UCIBIO-NOVA FCT was distinguished with a European Research Council (ERC) Proof of Concept grant with the project UNMASK: Unraveling Parkinson ́s disease diagnostic. This is the researcher’s third ERC Grant, ensuring continuous funding from the council since 2014 for her work in non-invas
UCIBIO study finds a switch to activate carbon dioxide reduction in oxygen-resistant enzyme A new study, published in Nature Chemical Biology, by researchers from the Macromolecular Crystallography research lab at UCIBIO-NOVA, in collaboration with the group of Ines C Pereira at ITQB-NOVA, revealed how a formate dehydrogenase can withstand oxygen exposure.